| Previous Close | 4.27 |
| Open | 4.30 |
| Volume | 598,027 |
| Avg. Volume (3M) | 1,882,343 |
| Market Cap | 533,681,856 |
| Price / Sales | 25.39 |
| Price / Book | 2.42 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -0.550 |
| Total Debt/Equity (MRQ) | 1.86% |
| Current Ratio (MRQ) | 22.35 |
| Operating Cash Flow (TTM) | -52.67 M |
| Levered Free Cash Flow (TTM) | -68.15 M |
| Return on Assets (TTM) | -11.05% |
| Return on Equity (TTM) | -19.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | I-MAB | Mixed | Bullish |
AIStockmoo Score
-0.7
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | -0.67 |
|
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 10.80% |
| % Held by Institutions | 29.64% |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |